These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

741 related articles for article (PubMed ID: 17335769)

  • 21. Peroxisome proliferator-activated receptors and inflammation.
    Moraes LA; Piqueras L; Bishop-Bailey D
    Pharmacol Ther; 2006 Jun; 110(3):371-85. PubMed ID: 16168490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, biological evaluation, and molecular modeling investigation of chiral phenoxyacetic acid analogues with PPARalpha and PPARgamma agonist activity.
    Fracchiolla G; Laghezza A; Piemontese L; Carbonara G; Lavecchia A; Tortorella P; Crestani M; Novellino E; Loiodice F
    ChemMedChem; 2007 May; 2(5):641-54. PubMed ID: 17357171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CoMFA analysis of dual/multiple PPAR activators.
    Shah P; Mittal A; Bharatam PV
    Eur J Med Chem; 2008 Dec; 43(12):2784-91. PubMed ID: 18321611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.
    Fracchiolla G; Laghezza A; Piemontese L; Tortorella P; Mazza F; Montanari R; Pochetti G; Lavecchia A; Novellino E; Pierno S; Conte Camerino D; Loiodice F
    J Med Chem; 2009 Oct; 52(20):6382-93. PubMed ID: 19775169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peroxisome proliferator-activated receptor alpha and gamma ligands differentially affect smooth muscle cell proliferation and migration.
    Zahradka P; Wright B; Fuerst M; Yurkova N; Molnar K; Taylor CG
    J Pharmacol Exp Ther; 2006 May; 317(2):651-9. PubMed ID: 16407462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
    Cha DR; Zhang X; Zhang Y; Wu J; Su D; Han JY; Fang X; Yu B; Breyer MD; Guan Y
    Diabetes; 2007 Aug; 56(8):2036-45. PubMed ID: 17536062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-throughput fluorescence polarization method for identifying ligands of LOX-1.
    Zhang TT; Huang ZT; Dai Y; Chen XP; Zhu P; Du GH
    Acta Pharmacol Sin; 2006 Apr; 27(4):447-52. PubMed ID: 16539845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peroxisome proliferator-activated receptors and acute lung injury.
    Cuzzocrea S
    Curr Opin Pharmacol; 2006 Jun; 6(3):263-70. PubMed ID: 16580256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a complex scintillation proximity assay for high-throughput screening of PPARgamma modulators.
    Wu B; Gao J; Wang MW
    Acta Pharmacol Sin; 2005 Mar; 26(3):339-44. PubMed ID: 15715931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of phthalate ester derivatives including oxidized metabolites on coactivator recruiting by PPARalpha and PPARgamma.
    Kusu R; Oishi A; Kakizawa K; Kimura T; Toda C; Hashizume K; Ueda K; Kojima N
    Toxicol In Vitro; 2008 Sep; 22(6):1534-8. PubMed ID: 18602795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C333H, a novel PPARalpha/gamma dual agonist, has beneficial effects on insulin resistance and lipid metabolism.
    Xu C; Wang LL; Liu HY; Zhou XB; Cao YL; Li S
    Acta Pharmacol Sin; 2006 Feb; 27(2):223-8. PubMed ID: 16412273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ligand-dependent nucleo-cytoplasmic shuttling of peroxisome proliferator-activated receptors, PPARα and PPARγ.
    Umemoto T; Fujiki Y
    Genes Cells; 2012 Jul; 17(7):576-96. PubMed ID: 22646292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PPARs as therapeutic targets in cardiovascular disease.
    van Bilsen M; van Nieuwenhoven FA
    Expert Opin Ther Targets; 2010 Oct; 14(10):1029-45. PubMed ID: 20854178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro screening of 200 pesticides for agonistic activity via mouse peroxisome proliferator-activated receptor (PPAR)alpha and PPARgamma and quantitative analysis of in vivo induction pathway.
    Takeuchi S; Matsuda T; Kobayashi S; Takahashi T; Kojima H
    Toxicol Appl Pharmacol; 2006 Dec; 217(3):235-44. PubMed ID: 17084873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis of novel PPARα/γ dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design program PROTOBUILD.
    Bhurruth-Alcor Y; Røst T; Jorgensen MR; Kontogiorgis C; Skorve J; Cooper RG; Sheridan JM; Hamilton WD; Heal JR; Berge RK; Miller AD
    Org Biomol Chem; 2011 Feb; 9(4):1169-88. PubMed ID: 21157612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quinoline-based derivatives of pirinixic acid as dual PPAR alpha/gamma agonists.
    Popescu L; Rau O; Böttcher J; Syha Y; Schubert-Zsilavecz M
    Arch Pharm (Weinheim); 2007 Jul; 340(7):367-71. PubMed ID: 17610302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist.
    Chen Q; Chen J; Sun T; Shen J; Shen X; Jiang H
    Anal Biochem; 2004 Dec; 335(2):253-9. PubMed ID: 15556564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Additivity of molecular fields: CoMFA study on dual activators of PPARalpha and PPARgamma.
    Khanna S; Sobhia ME; Bharatam PV
    J Med Chem; 2005 Apr; 48(8):3015-25. PubMed ID: 15828840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.
    Lin CH; Peng YH; Coumar MS; Chittimalla SK; Liao CC; Lyn PC; Huang CC; Lien TW; Lin WH; Hsu JT; Cheng JH; Chen X; Wu JS; Chao YS; Lee HJ; Juo CG; Wu SY; Hsieh HP
    J Med Chem; 2009 Apr; 52(8):2618-22. PubMed ID: 19301897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peroxisome proliferator-activated receptor alpha, delta, gamma1 and gamma2 expressions are present in human monocyte-derived dendritic cells and modulate dendritic cell maturation by addition of subtype-specific ligands.
    Jakobsen MA; Petersen RK; Kristiansen K; Lange M; Lillevang ST
    Scand J Immunol; 2006 May; 63(5):330-7. PubMed ID: 16640656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.